2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Pathology, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Bleeding and Clotting, Bleeding Disorders, Thromboembolism, Thrombotic Disorders, VWD, Immunology, Autoimmune Disorders, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

1309 Factor h host-recognition domains confer tissue-specific protection in renal and extrarenal vascular beds

Jing Hu, MD, Takashi Miwa, PhD2, Eshagh Mohammadyari, MD3, Madhu Golla, PhD4, Lakshmi Pravallika Poka, PhD5, Isba Riaz6, William Halle7, Lin Zhou8, Wen-Chao Song9
1 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Background: Factor H (FH) is the principal regulator of alternative pathway (AP) complement activation, and FH mutations are associated with atypical hemolytic uremic syndrome (aHUS). Gangrene, characterized by ischemia and necrosis of distal extremities, occurs in a subset of aHUS patients, but a direct link between FH dysfunction and gangrene has not been established. Here, we describe a mouse model of complement-mediated gangrene resulting from FH dysfunction.

Methods: We studied an FH hypomorphic mutant mouse (FHm/m) expressing trace amounts of FH SCR1-18, resulting in plasma C3 and factor B (FB) consumption, prominent glomerular C3 deposition, and mild C3 glomerulopathy. Mice were treated with adeno-associated virus 8 (AAV8) vectors encoding IgG1-Fc fusion proteins containing FH SCR1-4 alone, FH SCR1-4/6-8, FH SCR1-4/19-20, or FH SCR1-4/6-8/19-20. These constructs retain fluid-phase AP regulatory activity but differ in host cell-binding domains. Mice were followed for 6 weeks.

Results: All FH fusion proteins were persistently expressed in plasma and restored C3 and FB levels to various degrees. FH SCR1-4-Fc achieved the highest circulating concentration, likely due to the absence of host cell-binding domains. Both FH SCR1-4-Fc and FH SCR1-4/19-20-Fc normalized plasma C3 and FB, whereas FH SCR1-4/6-8-Fc and FH SCR1-4/6-8/19-20-Fc only partially restored C3 and FB levels. At the endpoint, the mean values in mice treated with FH SCR1-4-Fc, FH SCR1-4/19-20-Fc, FH SCR1-4/6-8-Fc, and FH SCR1-4/6-8/19-20-Fc were 28.31 μM, 13.78 μM, 1.93 μM, and 0.93 μM, respectively. Unexpectedly, mice treated with FH SCR1-4/6-8-Fc developed severe tail necrosis, gangrene, and stroke-related mortality, whereas those receiving FH SCR1-4-Fc, FH SCR1-4/19-20, or FH SCR1-4/6-8/19-20-Fc did not. FH SCR1-4/6-8-Fc partially, and FH SCR1-4-Fc, FH SCR1-4/19-20-Fc, and FH SCR1-4/6-8/19-20-Fc completely, prevented glomerular C3 deposition. FH SCR1-4/6-8-Fc shows stronger binding to human umbilical vein endothelial cells compared with FH SCR 1-4/19-20-Fc. Despite gangrene development, FHm/m mice treated with FH1-4/6-8-Fc showed no abnormalities in urinalysis, complete blood count, or renal pathology.

Conclusions: These findings establish a mouse model of complement-mediated gangrene and suggest that distinct FH host-recognition domains confer tissue-specific protection in renal and extrarenal vascular beds. The lack of gangrene and renal disease as assessed by urinalysis and glomerular C3 deposition in FHm/m mice treated with FH1-4-Fc suggested cell-binding domains are dispensable when FH levels are high.

Jing Hu, MD: No relevant conflicts of interest to declare.